Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asymptomatic Waldenstrom's macroglobulinemia.

R Alexanian1, D Weber, K Delasalle

  • 1University of Texas M.D. Anderson Cancer Center, Houston 77030-4009, USA.

Seminars in Oncology
|April 30, 2003
PubMed
Summary

Approximately 27% of Waldenstrom's macroglobulinemia (WM) patients have asymptomatic disease with slow progression. These patients can be monitored without immediate treatment, as outcomes are similar to those treated promptly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracortical BCI Performance is Robust to Changes in Attentional Load During Dual-Tasking.

bioRxiv : the preprint server for biology·2026
Same author

Expert-Level Detection of Epilepsy Markers in EEG on Short and Long Timescales.

NEJM AI·2025
Same author

Awareness of bone strength in patients with neuromuscular disorders: ERN EURO-NMD clinician survey and European patient survey.

Journal of the neurological sciences·2025
Same author

Building consensus on clinical outcome assessments for BCI devices. A summary of the 10th BCI society meeting 2023 workshop.

Journal of neural engineering·2024
Same author

Fecal Microbiota Transfer in Acute Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation.

Visceral medicine·2024
Same author

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Scientific reports·2023

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Waldenstrom's macroglobulinemia (WM) is a rare lymphoproliferative disorder.
  • Understanding the natural history of asymptomatic WM is crucial for patient management.

Purpose of the Study:

  • To determine the frequency and natural history of asymptomatic Waldenstrom's macroglobulinemia (WM).
  • To identify prognostic factors for disease progression in asymptomatic WM patients.
  • To compare outcomes of asymptomatic WM patients with those of symptomatic WM.

Main Methods:

  • Retrospective analysis of 132 newly diagnosed patients with monoclonal IgM.
  • Categorization into symptomatic WM, asymptomatic WM, and monoclonal gammopathy of undetermined significance (MGUS).
  • Evaluation of clinical features, hemoglobin (Hgb), serum beta(2)-microglobulin (B(2)M), and IgM levels.

Related Experiment Videos

Main Results:

  • 27% of patients (31/132) presented with asymptomatic WM.
  • Asymptomatic WM patients had higher Hgb, lower B(2)M, and similar IgM peaks compared to symptomatic WM.
  • Median time to progression for asymptomatic WM was 6.9 years; prognostic factors for early progression identified.

Conclusions:

  • A significant proportion of WM patients are asymptomatic at diagnosis and experience slow disease progression.
  • Asymptomatic WM patients can be safely monitored without immediate therapy if risks are low.
  • Treatment outcomes for asymptomatic WM patients are comparable to those treated promptly for overt disease.